MOB-015 N.A. phase 3 study - No N.A. launch
Moberg/Bayer abondoning N.A. launch, Moberg will focus on E.U.
Looks like Cipher won't have MOB-015 in their quiver anymore, they will communicate a decision in due course.
Probably see a sell off tomorrow or is this mostly priced in due to earlier (Sept.) study results? We'll see.
https://cipher.investorroom.com/2024-12-10-Cipher-Pharmaceuticals-Partner-Moberg-Pharma-AB-Reports-Topline-Data-in-MOB-015-Phase-3-Study